Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.

• PubMed
JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96. )| false
• Search Google Scholar
• Export Citation

Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37–42.

• PubMed
KarumanchiSAMerchanJSukhatmeVP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37–42. )| false
• Search Google Scholar
• Export Citation

DeVita VT Jr, Hellman S, Rosenberg SA et al.. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.

• PubMed
DeVitaVT JrHellmanSRosenbergSA. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. )| false
• Search Google Scholar
• Export Citation

Choyke PL. Hereditary renal cancers. Radiology 2003;226:33–46.

• PubMed
ChoykePL. Hereditary renal cancers. Radiology 2003;226:33–46. )| false
• Search Google Scholar
• Export Citation

Ries LAG, Melbert D, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.

• PubMed
RiesLAGMelbertDKrapchoM, eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007. )| false
• Search Google Scholar
• Export Citation

Hricak H, Demas BE, Williams RD et al.. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709–715.

• PubMed
HricakHDemasBEWilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709–715. )| false
• Search Google Scholar
• Export Citation

Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diag Imaging 1991;32:69–118.

• PubMed
JanusCLMendelsonDS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diag Imaging 1991;32:69–118. )| false
• Search Google Scholar
• Export Citation

Dechet CB, Zincke H, Sebo TJ et al.. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003;169:71–74.

• PubMed
DechetCBZinckeHSeboTJ. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003;169:71–74. )| false
• Search Google Scholar
• Export Citation

Hollingsworth JM, Miller DC, Dunn RL et al.. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:1175–1180.

• PubMed
HollingsworthJMMillerDCDunnRL. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:1175–1180. )| false
• Search Google Scholar
• Export Citation

Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment or renal cell carcinoma. Curr Urol Rep 2006;7:31–38.

• PubMed
ShuchBLamJSBelldegrunAS. Open partial nephrectomy for the treatment or renal cell carcinoma. Curr Urol Rep 2006;7:31–38. )| false
• Search Google Scholar
• Export Citation

Leibovich BC, Blute ML, Cheville JC et al.. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;17:1066–1070.

• PubMed
LeibovichBCBluteMLChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;17:1066–1070. )| false
• Search Google Scholar
• Export Citation

Lui KW, Gervais DA, Mueller PR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. Chang Gung Med J 2004;27:618–623.

• PubMed
LuiKWGervaisDAMuellerPR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. Chang Gung Med J 2004;27:618–623. )| false
• Search Google Scholar
• Export Citation

Lewin JS, Nour SG, Connell CF et al.. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 2004;232:835–845.

• PubMed
LewinJSNourSGConnellCF. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 2004;232:835–845. )| false
• Search Google Scholar
• Export Citation

Gill IS, Remer EM, Hasan WA et al.. Renal cryoablation: outcome at 3 years. J Urol 2005;173:1903–1907.

• PubMed
GillISRemerEMHasanWA. Renal cryoablation: outcome at 3 years. J Urol 2005;173:1903–1907. )| false
• Search Google Scholar
• Export Citation

Rouviere O, Bouvier R, Negrier S et al.. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol 2006;3:200–213.

• PubMed
RouviereOBouvierRNegrierS. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol 2006;3:200–213. )| false
• Search Google Scholar
• Export Citation

Messing EM, Manola J, Wilding G et al.. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214–1222.

• PubMed
MessingEMManolaJWildingG. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214–1222. )| false
• Search Google Scholar
• Export Citation

Clark JI, Atkins MB, Urba WJ et al.. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:3133–3140.

• PubMed
ClarkJIAtkinsMBUrbaWJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:3133–3140. )| false
• Search Google Scholar
• Export Citation

Trump DL, Elson P, Propert K et al.. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 253.

• PubMed
TrumpDLElsonPPropertK. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 253. )| false
• Search Google Scholar
• Export Citation

Kavolius JP, Mastorakos DP, Pavlovich C et al.. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261–2266.

• PubMed
KavoliusJPMastorakosDPPavlovichC. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261–2266. )| false
• Search Google Scholar
• Export Citation

Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340–342.

• PubMed
FossaSDKjolsethILundG. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340–342. )| false
• Search Google Scholar
• Export Citation

Flanigan RC, Mickisch G, Sylvester R et al.. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol 2004;171:1071–1076.

• PubMed
FlaniganRCMickischGSylvesterR. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol 2004;171:1071–1076. )| false
• Search Google Scholar
• Export Citation

Flanigan RC, Salmon SE, Blumenstein BA et al.. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–1659.

• PubMed
FlaniganRCSalmonSEBlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–1659. )| false
• Search Google Scholar
• Export Citation

Mickisch GH, Garin A, van Poppel H et al.. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–970.

• PubMed
MickischGHGarinAvan PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–970. )| false
• Search Google Scholar
• Export Citation

Negrier S, Escudier B, Lasset C et al.. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1273–1278.

• PubMed
NegrierSEscudierBLassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1273–1278. )| false
• Search Google Scholar
• Export Citation

Yang JC, Sherry RM, Steinberg SM et al.. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127–3132.

• PubMed
YangJCSherryRMSteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127–3132. )| false
• Search Google Scholar
• Export Citation

Dutcher JP, Fisher RI, Weiss G et al.. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157–162.

• PubMed
DutcherJPFisherRIWeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157–162. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Basik J, Murphy BA et al.. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296.

• PubMed
MotzerRJBasikJMurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296. )| false
• Search Google Scholar
• Export Citation

Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–896.

• PubMed
ChowLQEckhardtSG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–896. )| false
• Search Google Scholar
• Export Citation

Faivre S, Delbaldo C, Vera K et al.. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25–35.

• PubMed
FaivreSDelbaldoCVeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25–35. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Hutson TE, Tomczak P et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.

• PubMed
MotzerRJHutsonTETomczakP. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124. )| false
• Search Google Scholar
• Export Citation

Figlin RA, Hutson TE, Tomczak MD et al.. Overall survival with sunitinib versus interferon (IFN-)alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5024.

• PubMed
FiglinRAHutsonTETomczakMD. Overall survival with sunitinib versus interferon (IFN-)alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5024. )| false
• Search Google Scholar
• Export Citation

Wilhelm SM, Carter C, Tang L et al.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.

• PubMed
WilhelmSMCarterCTangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109. )| false
• Search Google Scholar
• Export Citation

Moore M, Hirte HW, Siu L et al.. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688–1694.

• PubMed
MooreMHirteHWSiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688–1694. )| false
• Search Google Scholar
• Export Citation

Strumberg D, Richly H, Hilger RA et al.. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–972.

• PubMed
StrumbergDRichlyHHilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–972. )| false
• Search Google Scholar
• Export Citation

Awada A, Hendlisz A, Gil T et al.. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855–1861.

• PubMed
AwadaAHendliszAGilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855–1861. )| false
• Search Google Scholar
• Export Citation

Clark JW, Eder JP, Ryan D et al.. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472–5480.

• PubMed
ClarkJWEderJPRyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472–5480. )| false
• Search Google Scholar
• Export Citation

Szczylik T, Demkow M, Staehler F et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18S):5025.

• PubMed
SzczylikTDemkowMStaehlerF. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18S):5025. )| false
• Search Google Scholar
• Export Citation

Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res 1999;40:Abstract 301.

• PubMed
GibbonsJJDiscafaniCPetersonR. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res 1999;40:Abstract 301. )| false
• Search Google Scholar
• Export Citation

Hudes G, Carducci M, Tomczak P et al.. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.

• PubMed
HudesGCarducciMTomczakP. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281. )| false
• Search Google Scholar
• Export Citation

Yang JC, Haworth L, Sherry RM et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434.

• PubMed
YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434. )| false
• Search Google Scholar
• Export Citation

Escudier B, Pluzanska A, Koralewski P et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–2111.

• PubMed
EscudierBPluzanskaAKoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–2111. )| false
• Search Google Scholar
• Export Citation

Rini BI, Halabi S, Rosenberg JE et al.. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422–5428.

• PubMed
RiniBIHalabiSRosenbergJE. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422–5428. )| false
• Search Google Scholar
• Export Citation

Wenzel C, Locker G, Schmidinger M et al.. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney 2002;39:48–54.

• PubMed
WenzelCLockerGSchmidingerM. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney 2002;39:48–54. )| false
• Search Google Scholar
• Export Citation

Oevermann K, Buer L, Hoffmann R et al.. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583–587.

• PubMed
OevermannKBuerLHoffmannR. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583–587. )| false
• Search Google Scholar
• Export Citation

Stadler WM, Halabi S, Ernstoff MS et al.. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 4515.

• PubMed
StadlerWMHalabiSErnstoffMS. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 4515. )| false
• Search Google Scholar
• Export Citation

Nanus DM, Garino A, Milowsky MI et al.. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545–1551.

• PubMed
NanusDMGarinoAMilowskyMI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545–1551. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Escudier B, Oudard S et al.. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.

• PubMed
MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456. )| false
• Search Google Scholar
• Export Citation

Ratain MJ, Eisen T, Stadler WM et al.. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–2512.

• PubMed
RatainMJEisenTStadlerWM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–2512. )| false
• Search Google Scholar
• Export Citation

Escudier B, Eisen T, Stadler WM et al.. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.

• PubMed
EscudierBEisenTStadlerWM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134. )| false
• Search Google Scholar
• Export Citation

Eisen T, Bukowski RM, Staehler M et al.. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 4524.

• PubMed
EisenTBukowskiRMStaehlerM. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 4524. )| false
• Search Google Scholar
• Export Citation

Bukowski RM, Eisen T, Szczylik C et al.. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.

• PubMed
BukowskiRMEisenTSzczylikC. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Rini BI, Bukowski RM et al.. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–2524.

• PubMed
MotzerRJRiniBIBukowskiRM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–2524. )| false
• Search Google Scholar
• Export Citation